A Clinician View and Experience of Proteomic Studies in the Light of Lung Cancer in Japanese Healthcare
Forskningsoutput: Tidskriftsbidrag › Debate/Note/Editorial
In Japan, rising costs have impacted the framework of maintaining an efficient and effective healthcare system. Today, urgent implementation of programs to address this need have led to a rebuilding of the entire approach of medical evaluation and clinical care. Recent developments in clinical proteomics based on mass spectrometry (MS) for identifying, sequencing, and quantifying disease-relevant protein biomarkers is a promising means for optimal drug prescription using biomarker diagnosis. We illustrate in this report our experience with lung cancer cases with various drug therapies evaluated with proteomics studies.
|Enheter & grupper|
Ämnesklassifikation (UKÄ) – OBLIGATORISK